Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction (Q39122744)

9 September 2017

title

Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction (English)

1 reference

9 September 2017

Gina M Yanochko

1

1 reference

9 September 2017

Allison Vitsky

2

1 reference

9 September 2017

Jonathan R Heyen

3

1 reference

9 September 2017

Brad Hirakawa

4

1 reference

9 September 2017

Justine L Lam

5

1 reference

9 September 2017

Jeff May

6

1 reference

9 September 2017

Tim Nichols

7

1 reference

9 September 2017

Frederick Sace

8

1 reference

9 September 2017

Dusko Trajkovic

9

1 reference

9 September 2017

Eileen Blasi

10

1 reference

9 September 2017

publication date

20 July 2013

1 reference

9 September 2017

published in

Toxicological Sciences

1 reference

9 September 2017

volume

135

1 reference

9 September 2017

issue

2

1 reference

9 September 2017

page(s)

451-464

1 reference

FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

The FGF family: biology, pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Regulation of phosphate transport in proximal tubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Initial FGF23-mediated signaling occurs in the distal convoluted tubule

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

FGF23 induces left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Phosphate regulation of vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Regulation of fibroblast growth factor-23 signaling by klotho

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

FGFR3 and FGFR4 do not mediate renal effects of FGF23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Nitric oxide and adverse events of vascular endothelial growth factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Klotho converts canonical FGF receptor into a specific receptor for FGF23

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFT161

21 January 2018

Identifiers

DOI

10.1093/TOXSCI/KFT161

1 reference

9 September 2017

1 reference